Asset Details
Do you wish to reserve the book?
Bicarbonate therapy for prevention of chronic kidney disease progression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bicarbonate therapy for prevention of chronic kidney disease progression
Do you wish to request the book?
Bicarbonate therapy for prevention of chronic kidney disease progression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bicarbonate therapy for prevention of chronic kidney disease progression
2014
Overview
Kidney injury in chronic kidney disease (CKD) is likely multifactorial, but recent data support that a component is mediated by mechanisms used by the kidney to increase acidification in response to an acid challenge to systemic acid–base status. If so, systemic alkalization might attenuate this acid-induced component of kidney injury. An acid challenge to systemic acid–base status increases nephron acidification through increased production of endothelin, aldosterone, and angiotensin II, each of which can contribute to kidney inflammation and fibrosis that characterizes CKD. Systemic alkalization that ameliorates an acid challenge might attenuate the contributions of angiotensin II, endothelin, and aldosterone to kidney injury. Some small clinical studies support the efficacy of alkalization in attenuating kidney injury and slowing glomerular filtration rate decline in CKD. This review focuses on the potential that orally administered NaHCO3 prevents CKD progression and additionally addresses its mechanism of action, side effects, possible complications, dosage, interaction, galenic form description, and contraindications. Current National Kidney Foundation guidelines recommend oral alkali, including NaHCO3-, in CKD patients with serum HCO3- <22mmol/l. Although oral alkali can be provided by other medications and by base-inducing dietary constituents, oral NaHCO3 will be the focus of this review because of its relative safety and apparent efficacy, and its comparatively low cost.
Publisher
Elsevier Inc,Elsevier Limited
